Reimbursement Review Reports


( Last Updated : October 1, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clolar clofarabine Acute lymphoblastic leukemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Forxiga dapagliflozin Chronic kidney disease CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Oncaspar Pegaspargase CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zevalin Ibritumomab tiuxetan CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer